Paper: Smart Stop: A Phase II Study of Lenalidomide, Tafasitamab, Rituximab, and Acalabrutinib Alone and with Chemotherapy in Patients with Newly Diagnosed DLBCL
I want to highlight an exciting prospective trial for frontline treatment of DLBCL which will look at a potential “chemo free” approach. The SmartStop trial will look at the combination of Lenalidomide, Tafasitamab, Rituximab, and Acalabrutinib either alone or in combination with CHOP. There will be a cohort of patients that if they achieve a CR after 4 cycles of the chemo free regimen will go on to an additional 6 cycles of chemo free treatment. Presented here is just the trial design.
